Experimental Hematology & Oncology · Published 2026-08-03 · DOI 10.1186/s40164-026-00813-0
Tiantian Zhang, Heng Jiang, Delong Liu
Abstract Current Myeloproliferative neoplasm (MPN) therapies provide meaningful symptom and event-risk control but are limited by infrequent molecular remissions, treatment-limiting cytopenias (particularly anemia), and continued reliance on non–mutation-directed cytoreduction or phlebotomy with attendant morbidity. At ASH 2025 Annual Meeting, multiple investigational strategies aimed to address these limitations, including clone-directed targeting (INCA033989), phlebotomy-sparing physiologic therapy (rusfertide), and epigenetic disease-modifying combinations (pelabresib). We summarized the latest updates on these emerging agents and regimens for MPNs from the 2025 ASH Annual Meeting.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Zhang, T., Jiang, H., Liu, D. (2026). Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-026-00813-0